What is SDIX?
With a legacy spanning over three decades, SDIX has established itself as a critical infrastructure provider in the life sciences industry. The company specializes in the large-scale manufacturing of high-quality GMP antibodies, catering to a diverse clientele that includes anatomic pathology labs, biotechnology firms, and pharmaceutical enterprises. Their core competencies encompass the development of IHC antibodies and IVD reagents, alongside comprehensive contract manufacturing and custom formulation services. As a subsidiary of OriGene Technologies, SDIX integrates deep technical expertise with robust manufacturing standards, ensuring that its diagnostic solutions meet the rigorous commercialization objectives required by modern healthcare markets.
How much funding has SDIX raised?
SDIX has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in SDIX
PPP
Public-Private Partnership
What's next for SDIX?
The recent influx of capital signals a pivotal shift toward scaling production capabilities to meet the rising demand for high-precision diagnostic tools. Moving forward, SDIX is expected to prioritize the expansion of its contract manufacturing footprint, allowing the firm to support more complex pharmaceutical pipelines and large-scale IVD projects. By optimizing its supply chain and investing in advanced formulation technologies, the company aims to solidify its competitive advantage in the global biotechnology landscape. This strategic growth phase will likely focus on enhancing operational efficiencies and deepening partnerships within the pharmaceutical sector, ensuring that SDIX remains at the forefront of antibody-based diagnostic innovation.
See full SDIX company page
